Insight Molecular Diagnostics Inc. Payments to Acquire Equity Method Investments
Insight Molecular Diagnostics Inc. (IMDX) reported Payments to Acquire Equity Method Investments of $4.00 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-11.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireEquityMethodInvestments · last filed 2022-03-11
- Insight Molecular Diagnostics Inc. payments to acquire equity method investments for the quarter ending 2020-12-31 was $0.00.
- Insight Molecular Diagnostics Inc. payments to acquire equity method investments for the quarter ending 2020-09-30 was $0.00.
- Insight Molecular Diagnostics Inc. payments to acquire equity method investments for the quarter ending 2020-06-30 was -$2.19M.
- Insight Molecular Diagnostics Inc. payments to acquire equity method investments for the quarter ending 2020-03-31 was $6.19M.
- Insight Molecular Diagnostics Inc. payments to acquire equity method investments for fiscal 2020 was $4.00M, a 64.43% decline from fiscal 2019.
- Insight Molecular Diagnostics Inc. payments to acquire equity method investments for fiscal 2019 was $11.24M.
| Period end | Payments to Acquire Equity Method Investments 3 month | Payments to Acquire Equity Method Investments 6 month | Payments to Acquire Equity Method Investments 6 month as first filed | Payments to Acquire Equity Method Investments 9 month | Payments to Acquire Equity Method Investments 9 month as first filed | Payments to Acquire Equity Method Investments 12 month |
|---|---|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $0.00 derived: sum of 2 quarters · filed 2022-03-11 | -$2.19M derived: sum of 3 quarters · filed 2022-03-11 | $4.00M 10-K · filed 2022-03-11 | ||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$2.19M derived: sum of 2 quarters · filed 2021-11-09 | $4.00M 10-Q · filed 2021-11-09 | $6.19M 10-Q · filed 2020-11-12 | $4.00M derived: sum of 4 quarters · filed 2021-11-09 | |
| 2020-06-30 | -$2.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $4.00M 10-Q · filed 2021-08-11 | $6.19M 10-Q · filed 2020-07-29 | $4.00M derived: sum of 3 quarters · filed 2021-08-11 | ||
| 2020-03-31 | $6.19M 10-Q · filed 2020-05-12 | $6.19M derived: sum of 2 quarters · filed 2021-03-19 | ||||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-19 | $11.24M 10-K · filed 2021-03-19 | ||||
| 2019-09-30 | $11.24M 10-Q · filed 2019-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |